213 related articles for article (PubMed ID: 12757053)
1. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Wilson JW; Kelkar P; Frigas E
Int J Tuberc Lung Dis; 2003 May; 7(5):493-7. PubMed ID: 12757053
[TBL] [Abstract][Full Text] [Related]
2. Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Vesenbeckh SM; Becker J; Huhnt C; Karras B; Bauer TT; Mauch H; Rüssmann H; Schönfeld N
Infection; 2012 Apr; 40(2):199-202. PubMed ID: 21833615
[TBL] [Abstract][Full Text] [Related]
3. [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Mizutani H; Horiba M; Shindoh J; Kimura T; Son M; Wakahara K
Kekkaku; 2001 Oct; 76(10):667-72. PubMed ID: 11712388
[TBL] [Abstract][Full Text] [Related]
4. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
Takashima T; Danno K; Tamura Y; Nagai T; Matsumoto T; Han Y; Ano H; Yoshida H; Kawahara K; Tsuyuguchi I
Kekkaku; 2006 Jun; 81(6):413-8. PubMed ID: 16838679
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
7. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
[TBL] [Abstract][Full Text] [Related]
8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
9. [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Zheng XM; Li SM; Xing BC
Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):574-5, 578. PubMed ID: 15151838
[TBL] [Abstract][Full Text] [Related]
10. PAS infusion in treatment of multidrug-resistant tuberculosis.
Fodor T; Pataki G; Schrettner M
Int J Tuberc Lung Dis; 2000 Feb; 4(2):187-8. PubMed ID: 10694102
[No Abstract] [Full Text] [Related]
11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
12. [A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine].
Fujita J; Sunada K; Hayashi H; Hayashihara K; Saito T
Kekkaku; 2008 Jan; 83(1):21-5. PubMed ID: 18283911
[TBL] [Abstract][Full Text] [Related]
13. An outbreak of multidrug-resistant tuberculosis among refugees in Austria, 2005-2006.
Schmid D; Fretz R; Kuo HW; Rumetshofer R; Meusburger S; Magnet E; Hürbe G; Indra A; Ruppitsch W; Pietzka AT; Allerberger F
Int J Tuberc Lung Dis; 2008 Oct; 12(10):1190-5. PubMed ID: 18812050
[TBL] [Abstract][Full Text] [Related]
14. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
[TBL] [Abstract][Full Text] [Related]
15. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
16. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia.
Jugheli L; Rigouts L; Shamputa IC; Bram de Rijk W; Portaels F
Int J Tuberc Lung Dis; 2008 May; 12(5):561-6. PubMed ID: 18419893
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
[TBL] [Abstract][Full Text] [Related]
18. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
Van Deun A; Salim MA; Das AP; Bastian I; Portaels F
Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
[TBL] [Abstract][Full Text] [Related]
19. [Multidrug resistant tuberculosis in Iceland--case series and review of the literature].
Asgeirsson H; Blöndal K; Blöndal T; Gottfredsson M
Laeknabladid; 2009; 95(7-8):499-507. PubMed ID: 19553708
[TBL] [Abstract][Full Text] [Related]
20. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
